Quality of Life Research

, Volume 18, Issue 2, pp 267–272

Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D

Brief Communication

DOI: 10.1007/s11136-008-9429-z

Cite this article as:
Szende, A., Leidy, N.K., Ståhl, E. et al. Qual Life Res (2009) 18: 267. doi:10.1007/s11136-008-9429-z

Abstract

Objective

The objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.

Methods

This study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.

Results

Within each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.

Conclusions

Results suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D’s limited response options relative to mild disease.

Keywords

AsthmaChronic obstructive pulmonary disease (COPD)EQ-5DHealth utilitiesSF-6D

Abbreviations

COPD

Chronic obstructive pulmonary disease

EQ-5D

EuroQol-5D

GINA

Global initiative for asthma

GOLD

Global initiative for chronic obstructive lung disease

HRQL

Health-related quality of life

NHLBI

National Heart, Lung, and Blood Institute

OLIN

Obstructive Lung Disease in Northern Sweden

QALYs

Quality-adjusted life years

SF-6D

Short Form-6D

SG

Standard Gamble

TTO

Time trade-off

VAS

Visual analogue scale

WHO

World Health Organization

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • A. Szende
    • 1
  • N. K. Leidy
    • 2
  • E. Ståhl
    • 3
    • 4
  • K. Svensson
    • 5
  1. 1.Covance Market Access Services Inc.LeedsUK
  2. 2.United Biosource CorporationBethesdaUSA
  3. 3.AstraZeneca R&DLundSweden
  4. 4.University of AberdeenAberdeenUK
  5. 5.HEORConsultingLundSweden